RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S.

As of June 30, 2026, RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S. carries a market capitalization of 1.74B, placing it among publicly traded companies globally. Its enterprise value stands at 1.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S. has 500.00M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S. maintains a current ratio of 4.80, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S. recorded 210.79M in income tax expense.

As of the close on October 22, 2026, RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S.'s stock has declined approximately 42.48% over the past 52 weeks. The 50-day moving average sits at 2.51, while the 200-day moving average is 3.36.

As of June 30, 2026, RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S. holds 81.10M in cash and equivalents against 21.89M in total debt, resulting in a net debt position of -56.31M. Total book value stands at 2.92B, with working capital of 227.55M providing operational flexibility.

RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S. produced -1.76M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -26.01M in capital expenditures, free cash flow totaled -27.77M - equivalent to -0.06 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.60: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 3.87, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S. shareholders.

RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S.'s most recent stock split took place on March 19, 2025 with a 1:5 split ratio.